Supernus Q2 Falls To Loss, Despite 32% Revenue Jump; To Merge With Indivior In All-Stock Deal
Supernus Pharmaceuticals (SUPN) reported Q2 2026 net loss of $58.37M ($1.01/share) versus prior-year profit, despite 32% revenue growth to $219.1M. The loss reflected a $54.9M impairment charge tied to APOKYN. Supernus raised FY2026 revenue guidance to $860M-$890M and agreed to an all-stock merger with Indivior (INDV), expected to close in Q4 2026.
How this was made
The 30-second read
Why it matters
This article combines two tradable catalysts for Supernus: (1) Q2 results with a large impairment-driven loss and (2) a definitive all-stock merger agreement plus raised full-year 2026 guidance. Traders should model both fundamental guidance changes and deal-arbitrage/closing-risk effects.
Market read
Definitive M&A plus guidance raise creates a high-volatility setup for SUPN, with price action likely driven by deal terms, synergy expectations, and impairment normalization versus execution risk.
What to watch
Deal terms include a large $1.0B special cash dividend to Indivior shareholders and a fixed exchange ratio, which can affect post-close capital structure and near-term arbitrage dynamics; regulatory and shareholder approvals remain key.
Background
Supernus is a commercial-stage CNS biopharma with marketed products (e.g., Qelbree, GOCOVRI, ONAPGO) and a pipeline including SPN-443. The company also disclosed a definitive merger agreement with Indivior.
Ticker impact
Supernus reported a Q2 net loss of $58.37M tied to a $54.9M APOKYN impairment, while raising full-year 2026 guidance and announcing an all-stock merger with Indivior.
Likely elevated volatility with a bias to merger-related repricing, while earnings/guidance details may cap upside until investors underwrite synergy and impairment normalization.
The article discloses both a guidance raise and a definitive merger agreement, but the loss is largely impairment-driven (non-cash), and deal closing is still subject to approvals.
Market effects
CNS biopharma consolidation signal, potentially increasing investor focus on scale, commercial portfolio breadth, and cost-synergy feasibility.
Limited direct regional impact; primarily US-listed biotech sentiment and Nasdaq M&A flow.
Moderate, as the deal is cross-company but not described as globally systemic beyond CNS biopharma consolidation.
Counterpoint
The impairment is non-cash, so the market may overreact to the headline loss; the guidance raise and product sales mix could dominate if investors view APOKYN weakness as contained.
Key entities
- companySupernus Pharmaceuticals Inc.
Reported Q2 net loss driven by a $54.9M APOKYN impairment, raised 2026 revenue and adjusted operating earnings guidance, and agreed to merge with Indivior.
- companyIndivior Pharmaceuticals, Inc.
Definitive merger counterparty in a tax-free all-stock merger of equals, with Indivior shareholders receiving a $1.0B special cash dividend before close.
